We demonstrate synergistic cytotoxicity and tumor growth inhibition in PDAC cells, patient-derived organoids, and mouse models of PDAC when DHODHi are combined with a BCL-XL inhibitor (A-1331852) or degrader (DT2216). Here, BCL2L1 is linked to neoplasm.